Investigation of the Minimal Inhibitory Concentration Values of Vancomycin, Teicoplanin and Linezolid among MRSA Isolated from Inpatients by E-test Method
Introduction: Although studies aimed at the prevention of mortality and morbidity in MRSA infections have been ongoing for years, methicillin resistan Staphylococcus aureus (MRSA) remains one of the most important pathogens leading to nosocomial infections. In the treatment of cases infected by MRSA...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bilimsel Tip Yayinevi
2012-06-01
|
| Series: | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| Subjects: | |
| Online Access: | http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2012-17-02-068-074.pdf |
| Summary: | Introduction: Although studies aimed at the prevention of mortality and morbidity in MRSA infections have been ongoing for years, methicillin resistan Staphylococcus aureus (MRSA) remains one of the most important pathogens leading to nosocomial infections. In the treatment of cases infected by MRSA, the most important and most common issue is multi-drug resistance and the limited therapy
options. Today, in the therapy of MRSA infections, glycopeptide antibiotics such as vancomycin and teicoplanin and linezolid are the major therapeutic agents of choice. The aim of this study was to determine the minimal inhibitory concentration (MIC) values of vancomycin, teicoplanin and linezolid against MRSA strains isolated in our institution over a four year period, to compare with the results
from our country, and to contribute to the therapeutic options in MRSA infections. Materials and Methods: Between January 2006 and December 2009, vancomycin, teicoplanin and linezolid susceptibilities of 138 nonduplicate MRSA strains isolated from inpatients were determined by E-test method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Results: Resistance to vancomycin, teicoplanin and linezolide was not detected in MRSA strains isolated from inpatients in our hospital. MIC50 and MIC90 values for vancomycin, teicoplanin and linezolid were found 1.5 µg/mL and 2 µg/mL, 2 µg/mL and 4 µg/mL, and 0.75 µg/mL and 1 µg/mL, respectively. Conclusion: Our data are consistent with the data from our country. Our results indicate that linezolid could be used as a safe therapeutic option in addition to glycopeptides in the treatment of MRSA infections. |
|---|---|
| ISSN: | 1300-932X 1300-932X |